Provided by Tiger Fintech (Singapore) Pte. Ltd.

I-MAB

0.8303
-0.0144-1.70%
Volume:98.98K
Turnover:81.97K
Market Cap:67.67M
PE:-3.03
High:0.8566
Open:0.8070
Low:0.8012
Close:0.8447
Loading ...

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

GlobeNewswire
·
07 Mar

I-Mab initiated with a Buy at Brookline

TIPRANKS
·
28 Feb

I-Mab to Participate in Leerink Partners Global Healthcare Conference

GlobeNewswire
·
18 Feb

I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

GlobeNewswire
·
04 Feb

U.S. RESEARCH ROUNDUP-Antero Resources, IGM Biosciences, Lennar

Reuters
·
10 Jan

U.S. RESEARCH ROUNDUP-Accolade, Costco Wholesale, RH

Reuters
·
09 Jan

I-Mab : Needham Cuts Target Price to $4 From $6

THOMSON REUTERS
·
09 Jan

BRIEF-I-Mab Announces Open Market Purchases Of Company American Depositary Shares By Board Member

Reuters
·
08 Jan

I-Mab: Chairman Wei Fu Informed Co of His Intent to Purchase up to $2 Mln of Co's Adss

THOMSON REUTERS
·
08 Jan

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

THOMSON REUTERS
·
08 Jan

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

PR Newswire
·
08 Jan

US Penny Stocks To Watch In January 2025

Simply Wall St.
·
08 Jan

I-Mab to Prioritize Givastomig as Lead Program; Shares Rise

MT Newswires Live
·
07 Jan

BRIEF-I-MAB Announces Portfolio Prioritization Of Givastomig As Lead Clinical Program

Reuters
·
06 Jan

I-Mab Announces Portfolio Prioritization of Givastomig (Cldn18.2 X 4-1Bb Bispecific Antibody) as Lead Clinical Program

THOMSON REUTERS
·
06 Jan

I-Mab - Cash Balance of $184.4 Mln as of Sept 2024, Expected to Support Operations Into 2027

THOMSON REUTERS
·
06 Jan

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

PR Newswire
·
06 Jan

I-Mab Biopharma’s Strategic Shift to US-Based Biotech

TIPRANKS
·
04 Dec 2024

I-Mab to Participate at the Piper Sandler Healthcare Conference

PR Newswire
·
21 Nov 2024

I-Mab Third Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)

Simply Wall St.
·
17 Nov 2024